Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma
Autor: | Kongzhi Zhang, Shiguang Chen, Wenchang Yu, Weifu Liu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Adult
Diarrhea Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Pyridines Antineoplastic Agents Gastroenterology lcsh:RC254-282 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Genetics medicine Carcinoma Humans Apatinib Chemoembolization Therapeutic Adverse effect Transcatheter arterial chemoembolization Aged Neoplasm Staging Retrospective Studies business.industry Liver Neoplasms Cancer Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Survival Analysis BCLC Stage Treatment Outcome Oncology chemistry 030220 oncology & carcinogenesis Hepatocellular carcinoma Hypertension 030211 gastroenterology & hepatology Female BCLC Stage C Hepatocellular Carcinoma business Research Article |
Zdroj: | BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background Hepatocellular carcinoma (HCC) is a common cancer worldwide, with a poor prognosis. Most patients are diagnosed at advanced stages and are only eligible for palliative therapy. Therefore, this study aimed to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) treatment and TACE-alone treatment for Barcelona Clinic Liver Cancer stage C HCC. Methods We retrospectively reviewed 80 consecutive patients with BCLC stage C HCC who received TACE-apatinib or TACE-alone as the initial treatment. We compared the clinical and laboratory outcomes, imaging findings at 1 and 3 months after TACE, tumor response, time to progression (TTP), overall survival (OS), and adverse events between both groups. Results The overall response rate was higher in the TACE-apatinib group than in the TACE-alone group at 1 and 3 months after treatment (66.7% vs 39.6%, respectively, P = 0.020; 45.8% vs 17.6%, respectively, P = 0.021). The median TTP and OS in the TACE-apatinib group were longer than those of the TACE-alone group (TTP: 6.3 months vs 3.5 months, respectively, P = 0.002; OS: 13.0 months vs 9.9 months, respectively, P = 0.041). Apatinib-associated side effects such as hypertension, hand-foot syndrome, oral ulcers, proteinuria, and diarrhea were more prevalent in the TACE-apatinib group than in TACE-alone group (P |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |